Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 1998

View Archived Issues

Elan issues further update on development pipeline

Ibex: Q1 1999 highlights

Company Profile: Oxagen

Millennium delivers two additional drug targets for screening to Lilly

PathoGenesis reports encouraging phase II results for TOBI in bronchiectasis

Cambridge NeuroScience and Bayer to collaborate on GGF2 development

Immune Response announces phase IIb trial results for RA

Lilly develops novel 5-HT1A/5-HT1D antagonists for smoking cessation and CNS disorders

New series of 5-ht1F agonists disclosed by Lilly

Somatostatin agonists from Takeda claimed for diabetes and its complications

Patent assigned to Sumitomo describes new compounds for immune and inflammatory disorders

HSP-117: newly synthesized NK1 receptor antagonist with potent antiemetic effects

Disposition of L-732351, a semisynthetic macrolide immunosuppressant, in animals

Japanese approval sought for Accolate

Orphan drug status given to Immunomedics' CEA-Cide pancreatic cancer therapeutic

Design of potent MAP kinase p38 inhibitors reported by R.W. Johnson

Knoll and Hoechst Marion Roussel to codevelop treatment for CHF and hypertension

Another novel class of nonsteroidal progesterone receptor agonists designed by Ligand

FDA accepts Hyal's NDA for Solarase

Allelix and Lilly extend drug discovery alliance focusing on several therapeutic areas

Preliminary phase II results for Incel + paclitaxel in refractory breast cancer

Y5 antisense ODN used to confirm involvement of this receptor in the regulation of feeding

New cancer-linked gene licensed by Corixa from MIT

Oral human immunoglobulin proves to be safe and effective treatment for RA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...